Aydin Huseynov's questions to Urogen Pharma Ltd (URGN) leadership • Q4 2024
Question
Aydin Huseynov from Ladenburg inquired about the commercial preparedness for UGN-102, specifically the rationale for increasing the sales force from 52 to 83 reps for a market opportunity projected to be 10 times larger than JELMYTO's.
Answer
Chief Commercial Officer David Lin explained that the sales force size is based on patient epidemiology; unlike the rare disease JELMYTO treats, UGN-102's target patients are seen by most urologists, and 83 territories will cover about 85% of the market. President and CEO Liz Barrett added that this team is supported by a comprehensive field organization including nurse educators, MSLs, and reimbursement managers.